Michelle Wilcox
Adult Health · Hamilton, OHNPI 1689162075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,646 and has fallen 66.2% since, to $557 in 2025. Among adult health clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$834
- Johnson & Johnson$687
- AstraZeneca$686
- Novo Nordisk$381
- Biohaven Pharmaceuticals, Inc.$247
- Abbott$234
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $834 |
| Johnson & Johnson | 29 | $687 |
| AstraZeneca | 12 | $686 |
| Novo Nordisk | 19 | $381 |
| Biohaven Pharmaceuticals, Inc. | 11 | $247 |
| Abbott | 5 | $234 |
| Boehringer Ingelheim | 7 | $196 |
| Lilly USA, LLC | 9 | $134 |
| Teva Pharmaceuticals USA, Inc. | 1 | $121 |
| Gilead | 1 | $120 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| Pfizer | 6 | $92 |
| Bayer | 5 | $90 |
| Amgen | 5 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Merck | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Exeltis, USA Inc. | 3 | $45 |
| Dexcom, Inc. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Organon | 2 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| GSK | 1 | $14 |
| Novartis | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavyret$266
- BREZTRI$250
- FREESTYLE LIBRE 3$143
- NURTEC ODT$125
- Austedo XR$121
- AIRSUPRA$121
- Ozempic$121
- Epclusa$120
- XARELTO$120
- JARDIANCE$119
How this compares
$4,424 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $49,062 |
| TrulicityDulaglutide | 39 | $46,430 |
| JanuviaSitagliptin Phosphate | 29 | $29,776 |
| JardianceEmpagliflozin | 25 | $24,578 |
| OzempicSemaglutide | 15 | $14,768 |
| EliquisApixaban | 27 | $10,825 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,600 |
| TradjentaLinagliptin | 13 | $7,288 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $6,462 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,593 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 129 | $3,443 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,891 |
| Ventolin HfaAlbuterol Sulfate | 50 | $2,614 |
| Atorvastatin Calcium | 420 | $2,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $121 | $49,06211 claims |
| Lilly USA, LLCTrulicity | $134 | $46,43039 claims |
| Boehringer IngelheimJardiance, Tradjenta | $196 | $31,86638 claims |
| MerckJanuvia | $60 | $29,77629 claims |
| Novo NordiskOzempic | $381 | $14,76815 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $14,19327 claims |
| PfizerEliquis | $92 | $10,82527 claims |
| AstraZenecaSymbicort | $686 | $8,61625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.
Other adult health in Hamilton
- Deborah StevisonHamilton$10K
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Teresa ShafferBoardman$102K
- Jesse McClainYoungstown$79K
- Lucretia LongColumbus$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.